Adobe Stock
Anthem Biosciences made a cracking debut on the bourses today (July 21, 2025), listing at Rs 723 — a good 27 per cent higher than its issue price of Rs 570. The stock continued to climb during the day, reaching Rs 746. Investors who got in at the IPO price are cheering. But the question now is — has the easy money already been made?
Let’s peel back the layers.
Why it is in the spotlight
- The IPO was a pure offer for sale — no fresh capital raised. Existing investors cashed out to the tune of Rs 3,395 crore.
- Demand was hot. The issue was subscribed 67 times overall, with institutional investors (QIBs) bidding over 190 times.
- Grey market whispers had already hinted at a strong debut, and the listing lived up to the hype.
The market seems convinced that Anthem has both the science and the scale.
About the company
Based in Bengaluru, Anthem is what the pharma world calls a CRDMO — Contract Research, Development & Manufacturing Organisation. That’s just a fancy way of saying it helps drugmakers at every stage: From lab discovery to commercial manufacturing.
It operates across several niche areas like RNA interference, antibody-drug conjugates and oligonucleotides. Simply put, Anthem handles the brainwork and the grunt work for global pharmaceutical companies.
Should investors chase the rally?
If you got in at the IPO price, you’re sitting on decent gains. But for fresh investors, this is where things get tricky.
The company has a strong runway — global demand for outsourced pharma R&D and manufacturing is booming. Anthem’s integrated model puts it in a sweet spot. But at 70× earnings, there’s little room for error.
The stock is now in ‘show me’ territory. If growth stalls, the premium will shrink fast. But if the company delivers, the rally could still have legs.
Serious about wealth? So are we.
Join thousands of smart investors who rely on Value Research Stock Advisor for expert-picked stocks, time-tested strategies and long-term discipline.
Stop guessing. Start growing. Check it out now: Value Research Stock Advisor.
Disclaimer: This is not a stock recommendation. This story was created with the assistance of artificial intelligence and has been reviewed by human experts for accuracy and is intended for informational purposes only. Please take it with a pinch of salt and do your own research or consult a financial advisor before making investment decisions.
Ask Value Research 
New episodes every Friday 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
